Equity
€3,500 from €338,975 in 2024
Equity fell by 99% in 1 year.
ORTHERO
Lifetime
4 annual accounts with figures on one time axispeak €331,765 (2025)
€331,765▲ 6.8%
peak €238,032 (2024)
€235,963▼ 0.9%
peak €338,975 (2024)
€3,500▼ 99.0%
€402,113▲ 108%
Board1 name since 2021
1 directorBYTTEBIER Paul Antoon Beatrijs Madeleine
Documentsfilings and deeds
07-05-202685 days before the deadline
2025micro format
Dividend €571,438Equity from €338,975 to €3,500Debts from €193,384 to €402,113Investments €223,469Cash from €440,076 to €100,652
Key points
from the 2025 annual accountsTurnover
≈ €500,000 estimated
The micro format states no turnover.
Debts
€402,113 99% of the balance sheet
Suppliers 2%Taxes and wages 18%Other 80%
Of this, €323,380 falls due within a year.
Investments
€222,039 10.4 × depreciation
Green is investment, beige is depreciation. Land and buildings stand 216.0% higher than in 2024.
Liquidity
0.36 was 4.01 in 2024
Short-term debts rose from €111,279 to €323,380.
Position in the sector
0.9%
Lower solvency than 94% of companies in human health. Sector median 63.0% · 20,764 companies.
Checked score
90
Excellent
Financially stronger than 24% of micro companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 24,185 companies (NACE 86, micro).
About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%lowest value
01-2025: < 0.1%● unchanged vs 12-2024
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025
08-2025: < 0.1%● unchanged vs 07-2025
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: 0.1%▲ +0.1 percentage points vs 05-2026
07-2026: 0.1%● unchanged vs 06-2026
08-2026: 0.1%● unchanged vs 07-2026
09-2026: 0.1%● unchanged vs 08-2026
10-2026: 0.1%● unchanged vs 09-2026
11-2026: 0.1%● unchanged vs 10-2026highest value
Financial strengthAverage
Score breakdown
raises risk
1 change of registered office in 24 months
Equity €3,500 (0.9% of total assets)
lowers risk
Sector: Human health activities (NACE 86)
Liquidity: current ratio 0.36, cash €100,652, halved
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 5% of them on solvency, 9% on liquidity, 80% on profitability and 2% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 2,157 companies had the same profile as ORTHERO has now. Each dot stands for 6 companies, two years later.
94.1%
were still trading
2.8%
stopped another way
3.0%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of ORTHERO itself is lower: 0.1% within 12 months. It rests on far more data about ORTHERO than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 2,157 companies, not a prediction for ORTHERO. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 5% of 20764 sector peers (2025).
NBB · sector comparisonPosition among 20764 sector peers
Solvency
better than 5%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 07-05-2026, 85 days ahead of the deadline.
NBB · 4 filingsDeviation from the deadline
2025
85 days early
2024
155 days early
2023
12 days early
2022
34 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 4 accounts on average 72 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 2 June (3 of the last 4 accounts filed within 48 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
- BYTTEBIER Paul Antoon Beatrijs Madeleine founderdeed of 28-12-2021
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0779358970
Company renamed from Dr. Paul Byttebier, orthopedie to ORTHERO
Gazette deed
Incorporation
Founding capital of €3,500 · Founder: BYTTEBIER Paul Antoon Beatrijs Madeleine · Appointment: BYTTEBIER Paul Antoon Beatrijs Madeleine (director) · published on 28-12-2021 · Gazette deed
First establishment
Waalhovestraat 18, Ninove
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| ORTHERO Ninove | €405,613 | €331,765 | 0.9% | - |
| DR. GERALDINE ACCOU, OFTALMOLOGE Ghent | €436,388 | €349,813 | 0.6% | - |
| Dr. Marno van Lieshout Merelbeke-Melle | €424,153 | €340,169 | 54.5% | - |
| Marie MOUTHUY Frasnes-lez-Anvaing | €407,424 | €319,467 | 45.4% | - |
| DGA Médical Verlaine | €408,839 | €316,640 | 16.0% | - |
| Dr. Heleen Maes Roeselare | €390,951 | €347,788 | 63.4% | - |
| EYEFUNDUS Hamont-Achel | €385,452 | €344,334 | 38.3% | - |
These companies have the same main activity as ORTHERO: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €385,000 and €436,000, founded between 2021 and 2022.
Official details
Source: KBO- Status
- Active since 24-12-2021Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.325.498.7849404 Ninove, since 24-12-2021
- Financial year end
- 31 December
- Peppol
- Reachable since 04-07-2025
Annual accounts 2025
- €405,613▼ 23.8%
- Filing
- Filed on 07-05-2026, 85 days before the end of the filing period
Insights on ORTHERO
ORTHERO files the micro format. That format states no turnover. The gross margin rose from €22,217 in 2022 to €331,765 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about ORTHERO
- What is the company number of ORTHERO?
- The company number of ORTHERO is 0779.358.970. The VAT number is the same number with BE in front: BE 0779.358.970.
- Where is ORTHERO based?
- The registered office is at Waalhovestraat 18, 9404 Ninove.Company details
- What does ORTHERO do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of ORTHERO?
- ORTHERO is a private limited company (BV).
- When was ORTHERO founded?
- ORTHERO was founded on 24-12-2021.
- Is ORTHERO still active?
- Yes, ORTHERO is an active enterprise in the KBO register.
- What is the turnover of ORTHERO?
- The turnover in financial year 2025 is ≈ €500,000. This figure is estimated from the gross margin of €331,765 and 30 comparable companies (NACE 86220). It probably lies between €450,000 and €690,000.Financials
- Is ORTHERO profitable?
- In financial year 2025, ORTHERO made a profit of €235,963.
- Where can I find the annual accounts of ORTHERO?
- ORTHERO filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ORTHERO due?
- ORTHERO must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.